1. Home
  2. AIFC vs STIM Comparison

AIFC vs STIM Comparison

Compare AIFC & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIFC

AI Financial Corporation Common Stock

N/A

Current Price

$0.38

Market Cap

102.1M

Sector

Finance

ML Signal

N/A

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

HOLD

Current Price

$1.96

Market Cap

120.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIFC
STIM
Founded
N/A
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.1M
120.4M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
AIFC
STIM
Price
$0.38
$1.96
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
1.0M
2.1M
Earning Date
N/A
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.25
EPS
N/A
N/A
Revenue
N/A
$52,776,000.00
Revenue This Year
N/A
$11.10
Revenue Next Year
N/A
$11.92
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.80
52 Week High
$0.70
$4.84

Technical Indicators

Market Signals
Indicator
AIFC
STIM
Relative Strength Index (RSI) 19.06 56.77
Support Level N/A $1.21
Resistance Level $0.60 $2.22
Average True Range (ATR) 0.05 0.23
MACD -0.02 -0.00
Stochastic Oscillator 4.06 35.85

Price Performance

Historical Comparison
AIFC
STIM

About STIM Neuronetics Inc.

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

Share on Social Networks: